significant and of opposite sign. 2 , 3 This problem was of particular interest for our group, and extensive work was performed using a methodology based on absorbed dose measurements with ionization chambers. We found a plausible solution for this problem which can be of practical use when measurements for commissioning of different reporting modes of treatment planning system (TPS) algorithm are performed. Nevertheless, due to the comprehensiveness of this research, the results are prepared to be published as separate research elsewhere. In addition to these point dose
Đeni Smilovic Radojcic, David Rajlic, Bozidar Casar, Manda Svabic Kolacio, Nevena Obajdin, Dario Faj and Slaven Jurkovic
Vaneja Velenik, Ajra Secerov-Ermenc, Jasna But-Hadzic and Vesna Zadnik
function deteriorate with age as the elderly have more pain, insomnia and dispnea which all are a consequence of more morbidity. Surely the impact of morbidity on HRQL in our population will be the field of our further surveys. In conclusion, in this study we have derived, by common methodology, the Slovenian HRQL normative values. Gender, age and self-rated social class are the important confounders in the quality of life scores in our population. The expected mean scores reported could be used as a reference in the clinical interpretation of disease progress and
Martina Baur, Matthias Preusser, Maria Piribauer, Katarzyna Elandt, Marco Hassler, Marcus Hudec, Christian Dittrich and Christine Marosi
Frequent MGMT (06-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experience
Background. The aim of this retrospective study was to analyse the MGMT (06-methylguanine-DNA methyltransferase) promoter methylation status in long-term surviving (≥ 3 years) patients with glioblastoma multiforme (GBM).
Methods. The methylation status of the MGMT promoter was determined by bisulfite modification of the DNA and subsequent methylation-specific polymerase-chain-reaction (MSP). DNA was extracted from routinely formalin-fixed and paraffin-embedded tumour tissue samples.
Results. MSP yielded interpretable results in only 14 of 33 (42%) long-term surviving patients with GBM. A methylated band was seen in 3 of 14, methylated as well as unmethylated bands in 8 of 14 and an only unmethylated band in 3 of 14 patients, thus, yielding MGMT promoter methylation in 11 of 14 patients. The two groups of patients with methylated and unmethylated MGMT promoter status were too small to draw any firm statistical conclusions.
Conclusions. Long-term surviving patients with GBM have very frequently intratumoural MGMT promoter methylation. This phenomenon discriminates long-term survivors from a non-selected group of patients with GBM. The standardization of the MSP for the determination of the MGMT promoter methylation status seems to be necessary in order to make this methodology a more reliable one.
Dejan Zontar, Urban Zdesar, Dimitrij Kuhelj, Dean Pekarovic and Damijan Skrk
Background. The aim of the study was to systematically evaluate population exposure from diagnostic and interventional radiological procedures in Slovenia.
Methods. The study was conducted in scope of the “Dose Datamed 2” project. A standard methodology based on 20 selected radiological procedures was adopted. Frequencies of the procedures were determined via questionnaires that were sent to all providers of radiological procedures while data about patient exposure per procedure were collected from existing databases. Collective effective dose to the population and effective dose per capita were estimated from the collected data (DLP for CT, MGD for mammography and DAP for other procedures) using dose conversion factors.
Results. The total collective effective dose to the population from radiological in 2011 was estimated to 1300 manSv and an effective dose per capita to 0.6 mSv of which approximately 2/3 are due to CT procedures.
Conclusions. The first systematic study of population exposure to ionising radiation from radiological procedures in Slovenia was performed. The results show that the exposure in Slovenia is under the European average. It confirmed large contributions of computed tomography and interventional procedures, identifying them as the areas that deserve special attention when it comes to justification and optimisation.
Dražen Huić, Andrea Mutvar, Sandra Kinda-Bašić, Igor Aurer, Martina Ciglar, Darko Grošev, Ivo Radman, Boris Labar and Damir Dodig
Negative predictive value of F-18-FDG coincidence PET in patients with Hodgkin's disease and a residual mass after therapy: a retrospective diagnostic test study
Background. The aim of the study was to asses the negative predictive value (NPV) of FDG-PET performed with triple-head coincidence gamma camera after the first-line therapy or salvage therapy in patients with Hodgkin's disease (HD) compared by a long-term follow-up as a reference standard.
Methods. This retrospective diagnostic test study was done at the University Hospital Centre Zagreb between June 2001 and February 2008. The charts of 131 consecutive patients with Hodgkin's disease were reviewed. Seventy-three consecutive PET-negative patients (median age 28 years; range 12-80 years) with primary or recurrent biopsy confirmed lymphoma after the first-line therapy or salvage therapy were followed-up at least 12 months (median 23 months; range 12-69 months). All already performed 18F-FDG PET scans (using hybrid PET camera with triple head coincidence imaging capability within a few months after the completion of the therapy) were again visually interpreted by two board-certified nuclear medicine physicians who were blinded to any clinical or CT data. The negative predictive value of FDG-PET performed with triple-head coincidence gamma camera (Index test) was compared with a long-term follow-up as a reference standard.
Results. Out of 131 patients 73 turned-out to be PET-negative. Of those 73 PET-negative patients, 61 have been scanned after the first-line chemotherapy/radiotherapy, and only 3 of them relapsed in a follow-up (negative predictive value 0.95). Twelve patients with resistant disease have been scanned after the repeated therapy, and 4 of them relapsed in a follow-up period (negative predictive value 0.66).
Conclusions. This methodology with a triple-head coincidence gamma camera has a high negative predictive value. A negative PET scan can reassure patients and their doctors that the disease is not active.
Vladimir Gasic, Branka Zukic, Biljana Stankovic, Dragana Janic, Lidija Dokmanovic, Jelena Lazic, Nada Krstovski, Vita Dolzan, Janez Jazbec, Sonja Pavlovic and Nikola Kotur
Response to glucocorticoid (GC) monotherapy in the initial phase of remission induction treatment in childhood acute lymphoblastic leukemia (ALL) represents important biomarker of prognosis and outcome. We aimed to study variants in several pharmacogenes (NR3C1, GSTs and ABCB1) that could contribute to improvement of GC response through personalization of GC therapy.
Retrospective study enrolling 122 ALL patients was carried out to analyze variants of NR3C1 (rs33389, rs33388 and rs6198), GSTT1 (null genotype), GSTM1 (null genotype), GSTP1 (rs1695 and rs1138272) and ABCB1 (rs1128503, rs2032582 and rs1045642) genes using PCR-based methodology. The marker of GC response was blast count per microliter of peripheral blood on treatment day 8. We carried out analysis in which cut-off value for GC response was 1000 (according to Berlin-Frankfurt-Munster [BFM] protocol), as well as 100 or 0 blasts per microliter.
Carriers of rare NR3C1 rs6198 GG genotype were more likely to have blast count over 1000, than the non-carriers (p = 0.030). NR3C1 CAA (rs33389-rs33388-rs6198) haplotype was associated with blast number below 1000 (p = 0.030). GSTP1 GC haplotype carriers were more likely to have blast number below 1000 (p = 0.036), below 100 (p = 0.028) and to be blast negative (p = 0.054), while GSTP1 GT haplotype and rs1138272 T allele carriers were more likely to be blasts positive (p = 0.034 and p = 0.024, respectively). ABCB1 CGT (rs1128503-rs2032582-rs1045642) haplotype carriers were more likely to be blast positive (p = 0.018).
Our results have shown that NR3C1 rs6198 variant and GSTP1 rs1695-rs1138272 haplotype are the most promising pharmacogenomic markers of GC response in ALL patients.
Mario de Denaro and Paola Bregant
23 of the Diagnostic Imaging Council CT committee. College Park: American Association of Physicists in Medicine; January, 2008. Comprehensive methodology for the evaluation of radiation dose in x-ray computed tomography. Report of AAPM Task Group 111: The Future of CT Dosimetry. College Park: American Association of Physicists in Medicine; February, 2010. Rimondini A, Pozzi Mucelli R, De Denaro M, Bregant P, Dalla Palma L. Evaluation of image quality and dose in renal colic: comparison of different spiral
Ioana Rodean, Elisabeta Himcinschi, Alexandra Tirca and Daniel Cernica
: similarities and differences. Int J Cardiovasc Imaging. 2011;27:215-224. doi: 10.1007/s10554-010-9789-7. 11. Zhang BC, Karanasos A, Regar E. OCT demonstrating neoatherosclerosis as part of the continuous process of coronary artery disease. Herz. 2015;40:845-854. doi: 10.1007/s00059-015-4343-y. 12. Mehanna EA, Attizzani GF, Kyono H, Hake M, Bezerra HG. Assessment of coronary stent by optical coherence tomography, methodology and definitions. Int J Cardiovasc Imaging. 2011;27:259-269. doi: 10.1007/s10554-010-9793-y.
Petra Gulácsi-Bárdos, Éva Nieszner, Emese Tóth-Zsámboki, Katarína Vargová, Sarolta Leé, Zsófia Horváth, Máté Vámos, Róbert Gábor Kiss and István Préda
, Cruickshank JK. Glucose, insulin diabetes and mechanisms of arterial dysfunction. Clin Exp Pharmacol P. 2007;34:677-682. 5. Fichtlscherer S, Breuer S, Zeiher AM. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: further evidence for the existence of the “vulnerable” patient. Circulation. 2004;110:1926-1932. 6. Barac A, Campia U, Panza JA. Methods for Evaluating Endothelial Function in Humans. Hypertension. 2007;49: 748-760. 7. Cracowski JL, Minson CT, Salvat-Melis M, Halliwill JR. Methodological issues in the
Peter Rogel, Robert Hudej and Primoz Petric
target size on interobserver variability. Int J RadiatOncol Biol Phys 2012; 82: e265-72. 10. Choi HJ, Kim YS, Lee SH, Lee YS, Park G, Jung JH, et al. Inter- and intra-observer variability in contouring of the prostate gland on planning computed tomography and cone beam computed tomography. Acta Oncol 2011; 50: 539-46. 11. Remeijer P, Rasch C, Lebesque JV, van Herk M. A general methodology for three-dimensional analysis of variation in target volume delineation. MedPhys 1999; 26: 931-40. 12. Deurloo KE